Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting drug development research?
- PMID: 23343639
- PMCID: PMC3592259
- DOI: 10.1017/S1744133112000321
Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting drug development research?
Abstract
Infectious diseases are among the main causes of death and disability in developing countries, and they are a major reason for the health disparity between rich and poor countries. One of the reasons for this public health tragedy is a lack of lifesaving essential medicines, which either do not exist or badly need improvements. In this article, we analyse which of the push and pull mechanisms proposed in the recent literature may serve to promote research into neglected infectious diseases. A combination of push programmes that subsidise research inputs through direct funding and pull programmes that reward research output rather than research input may be the appropriate strategy to stimulate research into neglected diseases. On the one hand, early-stage (basic) research should be supported through push mechanisms, such as research grants or publicly financed research institutions. On the other hand, pull mechanisms, such as prize funds that link reward payments to the health impacts of effective medicines, have the potential to stimulate research into neglected diseases.
Figures
Similar articles
-
Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases.Drug Discov Today. 2020 Feb;25(2):274-291. doi: 10.1016/j.drudis.2019.10.015. Epub 2019 Nov 5. Drug Discov Today. 2020. PMID: 31704277 Review.
-
Building local research and development capacity for the prevention and cure of neglected diseases: the case of India.Bull World Health Organ. 2001;79(8):742-7. Epub 2001 Oct 24. Bull World Health Organ. 2001. PMID: 11545331 Free PMC article.
-
Perspectives on stimulating industrial research and development for neglected infectious diseases.Bull World Health Organ. 2001;79(8):735-41. Epub 2001 Oct 24. Bull World Health Organ. 2001. PMID: 11545330 Free PMC article.
-
Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.Lancet. 2010 Sep 11;376(9744):922-7. doi: 10.1016/S0140-6736(10)60669-1. Lancet. 2010. PMID: 20833303
-
Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.Health Aff (Millwood). 2012 Nov;31(11):2528-35. doi: 10.1377/hlthaff.2012.0235. Health Aff (Millwood). 2012. PMID: 23129684 Review.
Cited by
-
'If I had a hedge fund, I would cure diabetes': endogenous mechanisms for creating public goods.SN Bus Econ. 2021;1(10):120. doi: 10.1007/s43546-021-00115-z. Epub 2021 Sep 6. SN Bus Econ. 2021. PMID: 34778817 Free PMC article.
-
The Pharmaceutical Commons: Sharing and Exclusion in Global Health Drug Development.Sci Technol Human Values. 2015 Jan;40(1):3-29. doi: 10.1177/0162243914542349. Sci Technol Human Values. 2015. PMID: 25866425 Free PMC article.
-
Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional study.J Pharm Policy Pract. 2017 Jan 6;10:4. doi: 10.1186/s40545-016-0094-2. eCollection 2017. J Pharm Policy Pract. 2017. PMID: 28070339 Free PMC article.
-
D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside.Int J Mol Sci. 2024 May 23;25(11):5682. doi: 10.3390/ijms25115682. Int J Mol Sci. 2024. PMID: 38891871 Free PMC article. Review.
-
Toward the formation of a Companion Animal Parasite Council for the Tropics (CAPCT).Parasit Vectors. 2015 May 13;8:271. doi: 10.1186/s13071-015-0884-4. Parasit Vectors. 2015. PMID: 25963851 Free PMC article.
References
-
- Acemoglu D. Linn J. (2004), ‘Market size in innovation: theory and evidence from the pharmaceutical industry’, Quarterly Journal of Economics, 119(3): 1049–1090
-
- Berndt E. R., Glennerster R., Kremer M., Lee J., Levine R., Weizsäcker G. Williams H. L. (2007), ‘Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness’, Health Economics, 16(4): 491–511 - PubMed
-
- Buckup S. (2008), ‘Global public–private partnerships against neglected diseases: building governance structures for effective outcomes’, Health Economics, Policy and Law, 3: 31–50 - PubMed
-
- DiMasi J. A., Hansen R. W. Grabowski H. G. (2003), ‘The price of innovation: new estimates of drug development costs’, Journal of Health Economics, 22: 151–185 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical